You are here

  • Home
  • Archive
  • Volume 73, Issue 5
  • The differences of clinicopathologic characteristics among subgroups of reclassified HER2 fluorescence in situ hybridization (FISH) according to the ASCO/CAP 2018 breast cancer HER2 testing guidelines

Article metrics

Article menu

Download PDFPDF

Original research
The differences of clinicopathologic characteristics among subgroups of reclassified HER2 fluorescence in situ hybridization (FISH) according to the ASCO/CAP 2018 breast cancer HER2 testing guidelines

 

Online download statistics by month:

Online download statistics by month: November 2019 to November 2024

AbstractFullPdf
Nov 20193453529
Dec 20192323415
Jan 2020160247
Feb 202013457
Mar 202098118
Apr 20203983126
May 20203662420
Jun 20201491616
Jul 2020163118
Aug 2020123105
Sep 2020130106
Oct 2020971610
Nov 202016686
Dec 2020149124
Jan 202111252
Feb 202112199
Mar 202114748
Apr 202110423
May 20214583
Jun 2021732
Jul 2021921
Aug 20211887
Sep 2021934
Oct 20217661
Nov 202110431
Dec 20217932
Jan 20226940
Feb 202214421
Mar 202210451
Apr 202212533
May 202223244
Jun 2022190142
Jul 202217495
Aug 202216293
Sep 202217382
Oct 202221698
Nov 202215491
Dec 202220373
Jan 202312740
Feb 202317050
Mar 202316083
Apr 2023146153
May 2023152131
Jun 202326772
Jul 202318041
Aug 202310481
Sep 2023193167
Oct 2023228810
Nov 202313744
Dec 202314944
Jan 20245732
Feb 20245614
Mar 20246925
Apr 202476015
May 20246515
Jun 20245621
Jul 20244046
Aug 20242611
Sep 20243212
Oct 20243122
Nov 20246941
Total8077503323